Balchem (NASDAQ:BCPC) was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued on Thursday.

BCPC has been the topic of several other research reports. ValuEngine raised Balchem from a “hold” rating to a “buy” rating in a report on Thursday, August 30th. HC Wainwright began coverage on Balchem in a report on Tuesday, September 25th. They set a “buy” rating on the stock. Sidoti raised Balchem from a “neutral” rating to a “buy” rating and set a $127.00 price objective on the stock in a report on Tuesday, October 16th. Finally, Pivotal Research raised their price objective on Balchem from $85.00 to $95.00 and gave the stock a “hold” rating in a report on Friday, August 3rd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $122.33.

NASDAQ:BCPC opened at $90.12 on Thursday. The firm has a market capitalization of $2.91 billion, a P/E ratio of 30.75 and a beta of 0.97. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.82 and a current ratio of 3.42. Balchem has a 12 month low of $70.23 and a 12 month high of $117.79.

Balchem (NASDAQ:BCPC) last posted its earnings results on Tuesday, November 6th. The basic materials company reported $0.73 EPS for the quarter, beating the consensus estimate of $0.61 by $0.12. The firm had revenue of $155.04 million for the quarter, compared to analyst estimates of $163.66 million. Balchem had a return on equity of 14.51% and a net margin of 15.67%. Balchem’s revenue for the quarter was up 2.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.63 earnings per share. Analysts predict that Balchem will post 2.45 EPS for the current fiscal year.

Hedge funds have recently modified their holdings of the business. Bbva Compass Bancshares Inc. purchased a new position in shares of Balchem during the third quarter worth about $226,000. Zeke Capital Advisors LLC purchased a new position in shares of Balchem during the second quarter worth about $203,000. Cubist Systematic Strategies LLC purchased a new position in shares of Balchem during the second quarter worth about $218,000. Granahan Investment Management Inc. MA purchased a new position in shares of Balchem during the second quarter worth about $224,000. Finally, Sigma Planning Corp purchased a new position in shares of Balchem during the second quarter worth about $229,000. 88.48% of the stock is currently owned by institutional investors.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical, medical sterilization, and industrial markets in the United States and internationally. The company's Human Nutrition & Health segment supplies ingredients in the food and beverage industry.

Further Reading: What is a conference call?

Receive News & Ratings for Balchem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Balchem and related companies with MarketBeat.com's FREE daily email newsletter.